Table 2.
Biomarker | PLWH (n = 95) | p-value | Controls (n = 52) | p-value | ||
---|---|---|---|---|---|---|
Absence of plaque | Presence of plaque | Absence of plaque | Presence of plaque | |||
GDF-15 (pg/mL) | 764 (716–1,760) | 1,037 (584–1,112) | 0.04 | 415 (290–413) | 640 (419–973) | <0.001 |
FGF-21 (pg/mL) | 172 (86–290) | 224 (110–493) | 0.44 | 189 (90–326) | 184 (82–312) | 0.73 |
GLP-2 (pg/mL) | 1.9 (1.1–3.0) | 1.8 (1.5–3.6) | 0.84 | 2.8 (1.8–3.3) | 2.2 (1.7–3.0) | 0.60 |
suPAR (pg/mL) | 2,062 (1,699–2,828) | 2,772 (2,286–3,587) | 0.003 | 1,864 (1,660–2,225) | 2,331 (1,790–3,157) | 0.08 |
hsCRP (mg/L) | 5.0 (5.0–5.0) | 5.0 (5.0–5.0) | 0.14 | 5.0 (5.0–5.8) | 5.0 (5.0–5.0) | 0.54 |
Anti-CMV IgG (IU/mL) | 27.2 (23.5–32.2) | 28.7 (23.7–31.4) | 0.62 | 4.9 (0.0–24.2) | 13.6 (0.0–22.9) | 0.68 |
Anti-EBV IgG (Genway U) | 44.2 (35.9–47.3) | 42.8 (30.2–47.8) | 0.61 | 29.7 (16.8–42.6) | 42.1 (33.7–48.0) | 0.008 |
Medians and interquartile ranges are described. PLWH, people living with human immunodeficiency virus. The bold values indicate the significant values of p < 0.05.